1. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia
by Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L. O'Loughlin, Sheila N. J. Sait, Maurice Barcos, Carleton C. Stewart, and Maria R. Baer
Blood
Volume 98(12):
December 1, 2001
©2001 by American Society of Hematology

2. Erythropoietin-dependent acute monoblastic leukemia.Histopathology.
Erythropoietin-dependent acute monoblastic leukemia.Histopathology. Skin biopsy showing infiltration by monoblasts staining with lysozyme (panel A, × 50 magnification) and bone marrow aspirate smear showing acute monoblastic leukemia (panel B, × 200 magnification), both during EPO therapy. Bone marrow aspirate smear showing the absence of leukemia 3 weeks after the discontinuation of EPO therapy (panel C, × 50 magnification).
Udomsak Bunworasate et al. Blood 2001;98:
©2001 by American Society of Hematology

3. EPO receptor expression on CD13+ blasts and in vitro proliferation of CD13+ cells in response to EPO.Upper panels (A) demonstrate gating on blasts defined by forward scatter characteristics (FSC) versus side scatter characteristics (SSC) (left) and coexpres...
EPO receptor expression on CD13+ blasts and in vitro proliferation of CD13+ cells in response to EPO.Upper panels (A) demonstrate gating on blasts defined by forward scatter characteristics (FSC) versus side scatter characteristics (SSC) (left) and coexpression of the EPO receptor with CD45 (center) and CD13 (right) on cells in the gated region. Lower panels (B) demonstrate the incorporation of BrdU into CD13+ cells in the absence (left) and presence (right) of EPO. Increased DNA synthesis is seen in CD13+ cells in the presence of EPO.
Udomsak Bunworasate et al. Blood 2001;98:
©2001 by American Society of Hematology